Prosecution Insights
Last updated: November 20, 2026

Susanna Moore, USPTO Patent Examiner

Listed by the USPTO as MOORE, SUSANNA

Tech Center 1600 • Art Units: 1624 1625 1626

This examiner grants 68% of resolved cases

Analysis

MOORE, SUSANNA is assigned to Tech Center 1600 and Art Unit 1624. The profile covers 1271 resolved cases, with a 68.0% allowance rate, a 31.6% interview lift, and a median time to allowance of 1062 days. The listed companies are The Regents of the University of California, Globachem NV, and The Trustees of Columbia University in the City of New York. The listed firms are OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P., COOLEY LLP, and KLARQUIST SPARKMAN, LLP.

The substantial resolved-case volume supports portfolio-level review of prosecution patterns. The allowance rate is more than twice the interview lift, so the overall disposition measure is broader than the interview-associated measure. The 1062-day median provides a planning reference for applicants assessing expected prosecution duration. Counsel can use the listed institutions and firms to locate comparable matters and evaluate claim strategy, amendment practice, and interview timing. The figures should inform that review without replacing application-specific analysis of disclosure, prior art, and examiner positions.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

68.0%
Allow Rate
+8.0% vs TC avg
1,356
Total Applications
+31.6%
Interview Lift
1062
Avg Prosecution Days
Based on 1271 resolved cases, 2023–2026

Rejection Statute Breakdown

1.5%
§101 Eligibility
16.4%
§102 Novelty
17.5%
§103 Obviousness
40.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18584298 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS Final Rejection Genentech, Inc.
18283395 ALGOSTATIC AGENTS FOR PREVENTING TRANSITION FROM ACUTE TO CHRONIC PAIN Non-Final OA The Regents of the University of California
17753902 METHOD OF MAKING AND/OR ISOLATING ISOIDIDE, COMPRISING SELECTIVE ESTERIFICATION OF A MIXTURE OF DIANHYDROHEXITOL ISOMERS Final Rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
17676211 Compounds to Identify Beta-Lactamases, and Methods of Use Thereof Final Rejection The Regents of the University of California
18680689 SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1-((3-CHLORO-2-FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO Final Rejection Hoffmann-La Roche Inc.
18663097 FLUORINATED PHTHALOCYANINE COMPOUND, COLORING COMPOSITION, AND INKJET INK Non-Final OA FUJIFILM CORPORATION
18871590 CRYSTALLINE FORMS OF AN AKRIC3 DEPENDENT KARS INHIBITOR Non-Final OA Novartis AG
18277765 SMALL MOLECULE ALLOSTERIC MODULATORS OF CLASS B GPCR, THE PTHR, AND METHOD TO IDENTIFY THEM Final Rejection University of Pittsburgh - Of the Commonwealth System of Higher Education
18869346 NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF Non-Final OA The Johns Hopkins University
18038579 ENANTIOSELECTIVE ALKENYLATION OF ALDEHYDES Final Rejection AMGEN INC.
17911388 METHODS OF CONTROLLING OR PREVENTING INFESTATION OF PLANTS BY THE PHYTOPATHOGENIC MICROORGANISM CORYNESPORA CASSIICOLA, CERCOSPORA SOJINA AND/OR CERCOSPORA KIKUCHII Final Rejection SYNGENTA CROP PROTECTION AG
18715147 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER Final Rejection Vanderbilt University
18905925 DEUTERATED DERIVATIVES OF RUXOLITINIB Final Rejection Sun Pharmaceutical Industries, Inc.
17758492 TARGETED STEROID COMPOUNDS Non-Final OA Purdue Research Foundation
18276432 Branched Linkers for Antibody-Drug Conjugates and Methods of Use Thereof Non-Final OA R.P. Scherer Technologies, LLC
17912429 COMPOSITIONS AND METHODS FOR TREATMENT OF PATHOLOGIC PAIN ASSOCIATED WITH MALIGNANT GROWTH DISORDER Final Rejection Duke University
18292565 RAS/RAF BINDING INHIBITOR COMPOUND Non-Final OA NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
18014057 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES Non-Final OA REMIX THERAPEUTICS INC.
17620630 USE OF DISULFIRAM OR ITS DERIVATIVES FOR THE TREATMENT OF MITOCHONDRIAL DISEASES OR DYSFUNCTION Final Rejection Universite De Bordeaux
18646264 IBOGAINE AND NORIBOGAINE ANALOGS AND METHODS OF USE Non-Final OA Atai Therapeutics, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Susanna Moore's allowance rate?

68.0% of resolved applications examined by Susanna Moore were allowed (1,271 resolved cases), compared with 54.4% across Art Unit 1624 over the last five years.

Does an interview help with examiner Susanna Moore?

This examiner's interview lift is +31.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Susanna Moore take to allow a patent?

Applications allowed by Susanna Moore took 1,062 days on average from filing to allowance.

Which art unit does examiner Susanna Moore work in?

Susanna Moore examines applications in Art Unit 1624 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month